Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton ’s Tyrosine Kinase Inhibitors

This article reviews the two most common reasons for ibrutinib and acalabrutinib discontinuation, including adverse events as well as CLL progression. The data for specific CLL-directed therapies following BTKi discontinuation, including venetoclax, phosphatidylinositol 3-kinase inhibitors, cellular therapies, a nd ongoing clinical trials, are reviewed. An evidence-based sequencing algorithm for treatment of CLL following BTKi discontinuation is proposed.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research